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Abstract
Over the last decade it has become evident that in addition to producing antibody, B cells activate 
the immune system by producing cytokines and via antigen presentation. In addition, B cells also 
exhibit immunosuppressive functions via diverse regulatory mechanisms. This subset of B cells, 
known as regulatory B cells (Bregs), contributes to the maintenance of tolerance, primarily via the 
production of IL-10. Studies in experimental animal models, as well as in patients with autoimmune 
diseases, have identified multiple Breg subsets exhibiting diverse mechanisms of immune 
suppression. In this review, we describe the different Breg subsets identified in mice and humans, 
and their diverse mechanisms of suppression in different disease settings.
Keywords: B cell, Bregs, human, IL-10, immune-suppression, mouse, regulation, regulatory B cells, subsets
Introduction
Over the last decade, the role of regulatory B cells (Bregs) in 
suppressing pathological immune responses has been widely 
recognized (1). Bregs, as negative regulators of the immune 
system, prevent potentially damaging autoimmune and pro-
tective immune responses that can result in uncontrolled 
inflammation. The number of Bregs is therefore a crucial deter-
minant of how the immune system is regulated; too few Bregs 
can result in autoimmunity and other inflammatory disorders, 
whereas too many Bregs can cause immune suppression.
Multiple studies in both mice and humans have demon-
strated that Bregs suppress inflammatory responses pri-
marily via the provision of IL-10 (1). Thus, IL-10 is not just a 
marker for Breg identification but also an important mediator 
of immune suppression by Bregs. With the increased interest 
in Breg biology in recent years, many new subsets of Bregs 
and additional mechanisms of Breg-mediated suppression 
have been identified. In this review, we explore the recent 
advances in the phenotypic and functional diversity of Bregs, 
in both mice and humans. We also highlight the diseases 
associated with defects in Breg homeostasis.
Mouse Breg subsets
The evidence that B cells play an immune-regulatory role was 
first demonstrated in B-cell-deficient (µMT) mice that were 
unable to recover from experimental autoimmune encepha-
litis (EAE) (2). A  few years later, different approaches led 
to the identification that it was a specific subset of B cells, 
namely, those producing IL-10 that exerted this suppressive 
function. Chimeric mice with IL-10 deficiency restricted to B 
cells displayed a persistent pro-inflammatory Th1 response 
and did not recover from EAE (3).
Mizoguchi et al., who coined the term ‘regulatory B cells’, 
reported the existence of a discrete population of IL-10-
producing CD1dhi Bregs that expanded with progression 
of chronic intestinal inflammatory conditions. CD1dhi Bregs 
inhibited disease progression by down-regulating the inflam-
matory cascades associated with IL-1 and STAT3 activation 
(4). Simultaneously, our research group demonstrated that 
CD40-mediated activation of splenocytes induced the differ-
entiation of IL-10-producing B cells that upon adoptive trans-
fer suppress the arthritogenic Th1 response and the severity 
of collagen-induced arthritis (CIA) (5). The importance of 
endogenous Bregs in restraining excessive inflammation 
was demonstrated in mice lacking IL-10-producing B cells. 
In the absence of Bregs, mice developed an exacerbated 
arthritis (6). The exacerbation of disease was paralleled by 
an increase in Th1 and Th17 cells and a decrease in FoxP3
+ 
Tregs, compared with wild-type (WT) mice (6).
Because of its crucial role in mediating Breg suppression, 
IL-10 production is largely used as a marker for Breg iden-
tification (1). To date, a number of Breg subsets with over-
lapping phenotypes and functions have been identified in 
various mouse models. Table 1 summarizes the different Breg 
subsets in the mouse that have been reported in the literature.
Transitional 2-marginal zone precursor cells
Our laboratory initially described the immunosuppressive func-
tions of splenic transitional 2-marginal zone precursor (T2-MZP) 
B cells with a CD19+CD21hiCD23hiCD24hiIgMhiIgDhiCD1dhi  
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phenotype (7). Among the different B-cell subsets residing 
in the spleens of mice with arthritis, T2-MZP B cells were 
found to be the main producers of IL-10 after stimulation with 
collagen, and the only subset that displayed a suppressive 
capacity both in vivo and in vitro (7). The suppressive func-
tions of IL-10-producing T2-MZP B cells have since been 
confirmed in a variety of immune-mediated pathologies rang-
ing from autoimmune diseases to allergy and cancer (7,18–
21). Adoptive transfer of T2-MZP Bregs has been reported to 
control the progression of arthritis. The mechanism of T2-MZP 
Breg-mediated suppression of arthritis included increased 
Treg and reduced Th1/Th17 frequencies, in both cases medi-
ated by IL-10 (21). 
Unlike in arthritis, lupus-prone MRL-lpr mice lacked func-
tionally suppressive T2-MZP Bregs (18). However, this defect 
was not permanent and was restored after in vitro stimulation 
of T2-MZP B cells with agonistic anti-CD40 mAb. Transfer of 
CD40-activated T2-MZP Bregs inhibited the development of 
lupus in recipient mice via the induction of IL-10-producing 
Tregs (18). T2-MZP Bregs have also been shown to suppress 
ovalbumin-induced allergic airway inflammation by inducing 
the infiltration of FoxP3+ Tregs into the sensitized lung follow-
ing Schistosoma mansoni infection (20). Similarly, T2-MZP 
Bregs have been identified to suppress Helicobacter-induced 
gastric immunopathology by inducing IL-10-producing 
T-regulatory 1 (Tr1) cells (22). Furthermore, in a mouse model 
of transplantation, T2-MZP B cells from tolerized mice have 
been shown to prolong skin allograft survival by suppressing 
T-cell activation (23).
There are several other reports describing Breg subsets 
that share a partial T2-MZP Breg phenotype. Changes in the 
phenotype may be the result of adaptation of T2-MZP Bregs 
to the environment rather than existence of multiple Breg pro-
genitors. For example, IL-10-producing CD19+CD21hi B cells 
have been shown to repress antitumor immunity during squa-
mous carcinogenesis (19). These cells express high levels of 
CD21 but not other markers, suggesting that other surface 
markers may have been down-regulated in response to spe-
cific stimuli present during the progression of cancer. IL-10-
producing Bregs induced by a granulocyte macrophage 
colony-stimulating factor (GM-CSF)–IL-15 fusion protein, 
known as GIFT15-Bregs, also share many surface markers 
with T2-MZP Bregs including CD21, CD23, CD24, CD1d, IgD 
and IgM (12). However, GIFT15-Bregs have lost the expres-
sion of CD19 and gained CD138 expression, giving them a 
phenotype that is also similar to plasma cells. Adoptive trans-
fer of GIFT15-Bregs suppressed the development of EAE via 
the production of IL-10 and by up-regulation of STAT-6 and 
MHC class II expression by GIFT15-Bregs (12).
In the spleen, along with T2-MZP B cells, their direct 
descendants—marginal zone (MZ) B cells—also express 
high levels of CD1d (24) and produce IL-10 and have been 
ascribed with regulatory properties. In response to Toll-like 
receptor (TLR) stimulation or apoptotic cells, MZ B cells 
produced the majority of IL-10 among B-cell subsets (8). 
Adoptive transfer of B cells stimulated with apoptotic cells 
protected mice from CIA via IL-10 release; however, the sup-
pressive capacity of purified MZ B cells was not assessed 
(8). More recently, MZ B cells have been reported to sup-
press antigen-specific CD8+ T-cell responses during early 
stages of Leishmania donovani infection (25).
B10 cells
Although MZ B cells express the highest levels of CD1d in the 
spleen, high expression of CD1d is a shared feature between 
different Breg subsets, both in mice and humans. However, the 
use of CD1d alone as a marker for the identification of Bregs 
is inadequate due to possible differences in gating strate-
gies or exposure of B cells to different inflammatory environ-
ments. The co-expression of CD1d and CD5 has been used 
to characterize a population of splenic B cells, which pro-
duce exclusively IL-10, known as B10 cells (9). CD1dhiCD5+ 
B10 cells have been shown to suppress inflammation in a 
variety of immune-related disorders upon ex vivo stimulation 
with LPS, phorbal 12-myristate 13-acetate (PMA), ionomycin 
and monensin (L+PIM) (9, 26). Their relevance in modulat-
ing immune responses was firstly demonstrated in an EAE 
model, in which depletion of B cells prior to disease induc-
tion resulted in severely exacerbated disease and increased 
T-cell infiltration into the central nervous system. Additionally, 
adoptive transfer of splenic B10 cells also ameliorated EAE, 
particularly if administered at an early stage of disease (27). 
The efficacy of B10 cells in dampening autoimmunity has 
been shown in several experimental models including arthri-
tis, lupus and intestinal inflammation (28–30). Similar to other 
Breg subsets, the induction of functionally suppressive B10 
cells requires both cognate interactions with activated CD4+T 
cells expressing CD40L as well as soluble mediators includ-
ing IL-21. B10 cells also require the expression of MHC-II, as 
Table 1. Phenotypes of mouse Breg subsets
Subtype Phenotype Mechanism of suppression References
T2-MZP B cells CD19+CD21hiCD23hiCD24hiIgMhiIgDhiCD1dhi IL-10 (7)
MZ B cells CD19+CD21hiCD23-CD24hiIgMhiIgDloCD1dhi IL-10 (8)
B10 cells CD19hiCD1dhiCD5+ IL-10 (9)
B-1a cells CD5+ IL-10 (10)
Killer B cells CD5+CD178+ FasL (11)
GIFT-15 B cells B220+CD21+CD22+CD23+CD24+
CD1d+CD138+IgD+IgM+
IL-10 (12)
Plasma cells CD138hiIgM+TACI+CXCR4+CD1dhiTim1int IL-10, IL-35 (13)
Plasmablasts CD138+CD44hi IL-10 (14)
TIM-1+B cells - IL-10 (15)
PD-L1hi B cells CD19+PD-L1hi PD-L1 (16)
— B220+CD39+CD73+ Adenosine (17)
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MHC-II-deficient mice lack functional B10 cells (31). We refer 
the readers to the extensive review on the function of B10 
cells in Reference (32).
CD138+ B cells
Until recently, Breg subsets were thought to be splenic B cells 
at a stage of development preceding terminally differentiated 
plasma cells (1). However, new emerging evidence suggests 
that B cells at later stages of development also produce IL-10 
and exhibit suppressive capacity. B10 cells were initially 
reported to differentiate into plasmablasts upon in vitro or in 
vivo activation; however, the regulatory capacity of the B10-
cell-derived plasmablasts was not assessed (33).
Matsumoto et al. have recently shown that IL-10-producing 
CD138+ plasmablasts in the draining lymph nodes (dLNs) of 
mice with EAE are crucial in suppressing autoimmune inflam-
mation by inhibition of dendritic cell function in pathogenic 
T-cell generation (14). They demonstrate that mice with B 
cells deficient in genes that control plasma cell differentia-
tion, Prdm1 and IRF4, develop more severe EAE compared 
with control mice. Furthermore, their data suggest that the 
suppression of disease by Bregs in EAE does not require 
splenic B cells. This observation is in opposition to most Breg 
studies showing that Bregs reside in the spleen. In particu-
lar, adoptive transfer of splenic B10 cells has been shown 
to suppress colitis, and it was suggested that they suppress 
disease before developing into antibody-secreting cells (33). 
Whether B10 cells migrate to the dLNs and differentiate into 
plasmablasts to exert suppressive function in vivo remains to 
be investigated.
Unlike CD138+ plasmablasts in the LNs, splenic CD138+ 
B cells can suppress inflammation in EAE as well as immune 
response to Salmonella infection via the provision of cytokines 
IL-10 and IL-35 (13). IL-35 is an immunosuppressive heter-
odimeric cytokine comprising two IL-12 family subunits, p35 
and EB13, and has been shown to be important for Treg-
mediated suppression (34, 35). In addition to inducing Tregs, 
IL-35 has recently been shown to induce Bregs producing 
both IL-10 and IL-35, conferring protection against experi-
mental autoimmune uveitis (EAU) (36). Adoptive transfer of 
IL-35-induced Bregs suppressed EAU by inhibiting Th1 and 
Th17 cells and promoting Tregs. It is noteworthy to mention 
that whereas in the above study, IL-35 was found to be impor-
tant in the generation of IL-10-producing Bregs; Shen et al. 
showed that IL-35 is also required in the effector phase of 
Bregs. Indeed, chimeric mice with B cells lacking the expres-
sion of either IL-35 subunit (p35 or EB13) or IL-10 developed 
equivalently exacerbated EAE and improved resistance to 
Salmonella typhimurium infection, compared with WT mice, 
suggesting that both cytokines contribute equally to the effec-
tor function of Bregs (13). The discrepancy between the two 
studies could be the result of different experimental disease 
models or the different stimulations used to expand Bregs. 
Despite the discordance, both studies provide strong sup-
port for immunosuppressive functions of IL-35+ Bregs. Taken 
together, CD138+ B cells may represent distinct populations 
of Breg subsets, or the same Breg subset that adapts to dif-
ferent environments in the spleen and LNs, and consequen-
tially releases different cytokines.
TIM-1+ B cells
T-cell Ig mucin domain-1 (TIM-1) is a transmembrane glyco-
protein that is associated with regulation of immune responses 
(37). TIM-1 is expressed by majority of IL-10-producing B 
cells in all major mouse Breg sub-populations, including 
T2-MZP B cells, B10 cells, CD138+ B cells and IgA+ plasmo-
cytes (13, 15, 38). There is also emerging evidence identify-
ing the regulatory capacity of TIM-1+ B cells in humans (39, 
40). Furthermore, TIM-1 ligation in mice prolonged allograft 
survival by the induction of Bregs. The importance of TIM-1 
in the maintenance and induction of IL-10-producing Bregs 
is highlighted by several independent studies. In one study, 
TIM-1 (mucin)–/– mice showed impaired IL-10 production 
leading to spontaneous systemic autoimmunity in aged mice, 
associated with hyperactive T cells and increased levels 
of circulating antibodies (41). TIM-1–/– mice have also been 
shown to spontaneously develop severe multiorgan tissue 
inflammation with age, due to defective IL-10 production by 
B cells, which was paralleled by an increase in pro-inflamma-
tory cytokine production (42). Moreover, adoptive transfer of 
TIM-1–/– B cells and WT T cells into Rag1–/– mice immunized 
with myelin oligodendrocyte glycoprotein (MOG) peptide 
resulted in a more severe EAE compared with mice co-trans-
ferred with WT B cells and WT T cells. TIM-1–/– B cells contrib-
uted to the severity of EAE by promoting increased Th1 and 
Th17 responses and by suppressing expansion of Tregs (42). 
In agreement with these data, another study has reported 
that TIM-1–/– mice displayed accelerated graft rejection due 
to defects in both baseline and induced IL-10+ Bregs (43). 
Moreover, they demonstrated that a single transfer of WT TIM-
1+ B cells to these mice could restore long-term graft survival. 
Of interest, both studies showed that whereas treatment with 
apoptotic cells expands IL-10-producing Bregs in WT mice, 
this does not occur in TIM-1–/– mice (42, 43). Collectively, the 
data suggest that TIM-1 is critical in both the maintenance 
and induction of Bregs under physiological conditions.
B-1a cells
While the majority of Breg subsets described are derived 
from ‘conventional’ B-2 cells, Bregs have also been identified 
within the B-1 lineage. B-1 cells are innate immune cells that 
produce the majority of natural antibodies, in particular IgM, 
to up-regulate the clearance of apoptotic cells (44). Because 
of its polyreactivity, natural IgM acts as a first line of defense 
against pathogens. B-1 cells can be further classified into 
functionally distinct subsets based on expression of CD5. 
CD5+ B-1 cells, known as B-1a cells, are major producers of 
IL-10 following innate activation (10).
B-1a cells were shown to be crucial in the control of TLR-
mediated lethal inflammation in neonatal mice by dampen-
ing excessive inflammation in an IL-10-dependent manner 
(45). Further studies revealed that B-1a cells expressing Fas 
ligand (FasL), denoted as killer B cells, mediate CD4+ T-cell 
apoptosis during schistosomal infection, thereby preventing 
granulomatous inflammation (11). The maximal FasL expres-
sion on B-1a cells was observed upon stimulation with IL-10, 
IL-4 and soluble egg antigens (46). Interestingly, it has also 
been shown that protection against colitis in TCRα-deficient 
mice kept in a conventional environment, unlike those housed 
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in pathogen-free conditions, was associated with expansion 
of IgM-producing B-1a cells (47). This was further supported 
by data showing that μMT/TCRα double-knockout mice kept 
in a conventional environment were not protected against 
colitis, suggesting that B-1a cells play a protective role in this 
model (47). Thus, innate B-1a Bregs could play an important 
role in immune regulation, as they not only neutralize invading 
pathogens but also suppress the inflammatory responses.
Other Breg subsets
There is an ever-increasing list of new phenotypic and 
functional markers associated with Bregs. Independent 
of IL-10 production, PD-L1hi B cells, interacting with 
CD4+CXCR5+PD-1+ T follicular helper (Tfh) cells, can limit 
both memory B-cell development and plasma cell differen-
tiation. Amelioration of EAE on adoptive transfer of PD-L1hi 
B cells to MOG-primed mice was associated with reduced 
Tfh expansion and generation of MOG-specific IgG. The sig-
nificance of these results is intriguing considering that B cells 
do not play a pathogenic role in this model and that B-cell-
deficient mice developed an exacerbated disease. Notably, 
PD-L1hi B cells showed resistance to anti-CD20 therapy by 
sequestering B-cell activating factor from the milieu and pro-
moting their survival (16). 
An elegant study using a mouse model of prostate can-
cer (PC) has identified IgA+ plasmocytes intratumorally, and 
shown that this B-cell subset can prevent oxaliplatin-mediated 
tumor-directed cytotoxic T-cell functions, via the expression 
of IL-10 and PD-L1 (38). Transforming growth factor (TGF)-β 
signaling and IgA class switch recombination were required 
for the development of this immune-suppressive Breg subset 
(38). Interestingly, IL-10-producing IgA+ plasmocytes were 
also identified in therapy-resistant and metastatic human PC, 
highlighting the potent immunosuppressive functions of this 
subset in cancer (38).
Additional mechanisms of immune suppression mediated 
by B cells include expression of CD39 and CD73, two ecto-
enzymes that together catalyze the dephosphorylation of 
adenine nucleotides to adenosine (17). Adenosine is known 
to suppress effector T-cell functions through binding to sev-
eral adenosine receptors (48). Whereas CD39 expression is 
common to B cells, CD73 expression is not; B-1 cells and 
B10 cells display high expression of CD73, whereas fewer 
B-2 cells express CD73. Transfer of CD73+ B cells to CD73-
deficient mice resulted in amelioration of severity of colitis, 
indicating that CD39+CD73+ B-cell adenosine can modulate 
colitis. An unexpected link between IL-10 and adenosine was 
observed in B-cell IL-10-deficient mice, wherein adenosine 
production was impaired due to reduced CD73 expression 
(17). Taken together, the current literature in mouse models 
highlights the diverse mechanisms of suppression employed 
by Bregs to limit excessive inflammation.
Human Breg subsets
In healthy individuals, Bregs are important in the mainte-
nance of immune homeostasis. Similar to mouse models, 
human Bregs are predominantly identified based on their 
ability to produce IL-10 (1). Patients with multiple sclerosis 
(MS) who were infected with helminths showed an increased 
frequency of IL-10-producing CD19+CD1dhi B cells and, most 
importantly, a better clinical outcome. The B cells isolated 
from MS patients with helminth infection suppressed T-cell 
proliferation as well as their IFN-γ production (49). Although, 
in human studies, it is difficult to conclusively pin down the 
exact mechanism of action, it was suggested that the amelio-
ration of disease symptoms in helminth-infected MS patients 
could be due to expansion of IL-10-producing B cells. To 
date, a number of reports describe different Breg subsets in 
humans and their mechanisms of suppression, summarized 
in Table 2.
CD24hiCD38hi Bregs
Bregs have been reported within the CD19+CD24hiCD38hi 
immature B-cell population in peripheral blood of healthy 
individuals (50). Upon in vitro CD40 engagement, 
CD19+CD24hiCD38hi B cells produced the highest amount 
of IL-10 among the B-cell subsets populating the peripheral 
blood and most importantly were the only subset to suppress 
Th1 differentiation. In addition to inhibiting Th1 responses and 
Th17 differentiation, CD19
+CD24hiCD38hi Bregs could also 
convert CD4+ T cells into Tregs and Tr1 cells (56). The inhibi-
tion of the Th1 response by Bregs was partially IL-10 depend-
ent and required CD80–CD86 interaction with T cells (50).
Numerical and functional CD19+CD24hiCD38hi Breg 
defects have been described in several autoimmune dis-
eases, including systemic lupus erythematosus (SLE) and 
rheumatoid arthritis (RA) (50,56,57). CD19+CD24hiCD38hi 
Bregs isolated from SLE patients show impaired IL-10 pro-
duction upon activation via CD40, but not TLR9, and are 
unable to suppress Th1 responses due to a defect in STAT3 
phosphorylation (50). It is hypothesized that the decreased 
IL-10 production might be a result of overstimulation of Bregs 
due to excessive inflammatory signals, leading to exhaustion 
and loss of suppressive function (1). In patients with active 
RA, Bregs were numerically impaired compared with healthy 
Table 2. Phenotypes of human Breg subsets
Subtype Phenotype Mechanism of suppression References
Immature B cells CD19+CD24hiCD38hi IL-10, PD-L1 (50)
B10 cells CD19+CD24hiCD27+ IL-10 (51)
GrB+B cells CD19+CD38+CD1d+IgM+CD147+ GrB, IL-10, IDO (52)
Br1 cells CD25hiCD71hiCD73lo IL-10, IgG4 (53)
Plasmablasts CD27intCD38hi IL-10 (14)
— CD39+CD73+ Adenosine (54)
iBregs — TGF-β, IDO (55)
482 The expanding family of regulatory B cells
individuals and were unable to induce Tregs or suppress Th17 
responses (56).
Studying the role of Bregs in SLE patients undergoing 
B-cell depletion (rituximab) therapy has provided useful 
insight into the contribution of Bregs to the maintenance of 
tolerance. In rituximab-treated patients, a higher immature to 
memory ratio has been associated with long-term remission 
(58, 59), suggesting that repopulation with immature Bregs 
might be associated with better disease outcome (1). This is 
supported by results in SLE patients treated with rituximab, 
where normalization of CD1d expression on newly repopu-
lated CD19+CD24hiCD38hi B cells corresponded to normali-
zation of the invariant natural killer T (iNKT) cell number and 
function, as well as improved clinical response (57). iNKT cell 
number and function were otherwise impaired in SLE patients, 
due to defective B-cell-mediated stimulation, associated with 
altered CD1d recycling (57). These studies reveal that the 
newly repopulated B cells that have reacquired the capacity 
to differentiate into Bregs can condition the response of other 
immunoregulatory cells.
Although primarily studied in autoimmunity, 
CD19+CD24hiCD38hi Bregs have been shown to participate 
in the immune response in infectious diseases and trans-
plantation. In patients with HIV infection, enrichment in IL-10-
producing CD19+CD24hiCD38hi Bregs has been shown to 
correlate positively with the viral load (60). In the same stud-
ies, Bregs were shown to suppress HIV-1-specific CD8+ T-cell 
responses via IL-10 production and possibly PD-L1 expres-
sion. Moreover, depletion of Bregs from PBMCs resulted in 
enhanced CD8+ T-cell effector function as well clearance of 
infected CD4+ T cells in vitro. More recently, blockade of IL-10R 
and PD-1–PD-L1 interaction confirmed that Bregs inhibit anti-
gen presentation, CD4+ T-cell proliferation and impaired anti-
HIV cytotoxic T lymphocyte functions in HIV-infected patients 
(61). These results suggest that CD19+CD24hiCD38hi Bregs 
may contribute to immune dysfunction in HIV infection and 
hinder viral eradication.
Recent studies from chronic graft-versus-host dis-
ease (cGVHD) have also highlighted the role of 
CD19+CD24hiCD38hi Bregs in establishing transplant tol-
erance by suppressing effector T-cell responses (62, 63). 
Bregs within the CD19+CD24hiCD38hi population as well 
as the CD19+IgM+CD27+ population displayed reduced 
IL-10-producing capacity in cGVHD patients, compared 
with patients without cGVHD and healthy donors (63). 
Furthermore, transplant-tolerant patients have been 
reported to display significantly higher IL-10-producing 
CD19+CD24hiCD38hi Bregs than immunosuppressed 
patients, but not healthy controls (64). More recently, it 
has been shown that the ratio of IL-10/TNF-α expression 
by CD19+CD24hiCD38hi B cells as a measure of cytokine 
polarization is a better indicator of Breg function than IL-10 
expression alone. Although renal transplant patients both 
with stable graft function as well as graft rejection displayed 
similar IL-10 expression levels by CD19+CD24hiCD38hi 
B cells, the IL-10/TNF-α ratio was lower in patients who 
subsequently displayed graft dysfunction (65). A  recent 
prospective study in kidney transplant patients con-
firmed the importance of Bregs in transplant tolerance, 
as CD19+CD24hiCD38hi B-cell numbers were found to be 
associated with reduced rejection rates (66). Thus, these 
studies support a critical role for Bregs as a biomarker and 
for therapeutic intervention in transplantation tolerance.
A recent study suggests the existence of immature B-cell-
derived regulatory plasmablasts in humans (14). Stimulation of 
naive immature B cells with CpG, IFN-α, IL-6 and IL-2 resulted 
in the maximal expansion of IL-10-producing CD27intCD38hi 
plasmablast-like cells with up-regulation of IRF4, Blimp1 and 
XBP1 expression. While this suggests a developmental link 
between immature Bregs and IL-10-producing plasmablasts, 
further studies will be necessary to determine whether imma-
ture B cells are really the precursors of regulatory plasma-
blasts. It remains to be ascertained whether in addition to 
producing IL-10, plasmablast-like B cells are also functionally 
suppressive. 
B10 cells
A population of IL-10-producing Bregs named B10 cells has 
recently been described in peripheral blood. The majority of 
the B10 cells were found within the CD19+CD24hiCD27+ B-cell 
sub-population, which via the production of IL-10 suppressed 
TNF-α production by monocytes. Unlike CD40-activated 
CD24hiCD38hi Bregs, human B10 cells respond to stimula-
tion with LPS and CpG (51). The frequency of B10 cells was 
reportedly increased in several systemic and organ-specific 
autoimmune diseases (51). We refer the readers to a fully 
comprehensive review on the role of B10 cells in health and 
disease in Reference 32. 
Other Breg subsets
Recent advances in our understanding of human Breg func-
tions have revealed an important role for Bregs in tumor 
immunology. A  study has shown that granzyme B (GrB)-
expressing B cells with a CD19+CD38+CD1d+IgM+CD147+ 
phenotype infiltrate tumors and regulate T-cell responses 
(52). GrB+ Bregs that were induced by IL-21 production by 
T cells also expressed IL-10, indoleamine-2,3-dioxygenase 
(IDO) and CD25 (52). More detailed experiments are required 
to better understand the role of GrB+ Bregs and to exploit 
their therapeutic potential.
Another subset of IL-10+ Bregs, known as B regulatory 1 
(Br1) cells, displays a CD25hiCD71hiCD73lo phenotype (53). 
These cells play an important role in allergen tolerance by 
suppressing antigen-specific CD4+ T-cell proliferation as 
well as by producing anti-inflammatory allergen-specific 
IgG4 antibodies and contributing to peripheral tolerance 
(53).
Independent of IL-10, circulating CD39+CD73+ B cells can 
drive a shift from an ATP-driven pro-inflammatory environ-
ment to an anti-inflammatory milieu induced by adenosine 
(54). As described above, CD39 and CD73 are ectonu-
cleotidases that hydrolyze exogenous ATP to adenosine 
5′-monophosphate (5′-AMP) and adenosine. While auto-
crine adenosine regulates B-cell responses, in vitro acti-
vated B cells down-regulated CD73 and inhibited CD4+ and 
CD8+ T-cell proliferation, possibly via production of 5′-AMP 
(54). The role of this novel mechanism of immune suppres-
sion by CD39+CD73+ B cells in health and disease requires 
further investigation.
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Another mechanism of Breg suppression involves the 
production of TGF-β and IDO and induces the expansion 
of IL-10+ and TGF-β+ Tregs (55). The expansion of these 
induced Bregs (iBregs) requires stimulation with CTLA-4 by 
T cells. Collectively, the emerging roles of human Bregs in 
maintaining homeostasis emphasize the importance of this 
population in restraining inflammatory responses.
Does a Breg lineage marker exist?
The multiple distinct, yet overlapping Breg phenotypes high-
light the need for more extensive characterization of both 
mouse and human Bregs to improve the current understand-
ing of Breg biology. Although IL-10 is still regarded as being 
crucial to Breg function, the identification of other diverse 
suppressive mechanisms raises several new possibilities. It 
remains to be seen whether functions are strictly restricted 
based on Breg phenotype. For these reasons, in vitro or in 
vivo suppression currently remains the gold standard for 
Breg identification (1).
The question of whether Bregs represent a dedicated func-
tional lineage or whether they represent multiple lineages is 
yet to be answered. Although the existence of a Treg-FoxP3-
equivalent transcription factor remains unknown, the possibil-
ity of a developmental relationship between the subsets cannot 
be excluded. Different Breg subsets could either arise from 
individual progenitors or could share a common progenitor. 
For instance, CD5, CD1d, CD21 and TIM-1 expression alone 
or in combination have been shown to ‘capture’ the majority of 
IL-10-producing Bregs in mice (13, 15, 38). It is possible that 
these markers identify Bregs at an early stage of differentiation 
but that their phenotype changes in response to the environ-
ment in which they reside. Another possibility is that the induc-
tion of Bregs is simply a consequence of the environmental 
milieu and that any B cell can acquire regulatory functions. 
This hypothesis is supported by the findings showing that 
stimulation with different combinations of cytokines induces 
different Breg subsets (31, 36, 67, 68). The proposed models 
of Breg development are summarized in Fig. 1.
The shared surface markers and mechanisms of sup-
pression between different Breg subsets both in mice 
and humans raise several interesting questions. Do the 
increased Bregs in experimental manipulations expand a 
preexisting population of Bregs? Moreover, if any B cell can 
acquire a Breg phenotype, is this a transient state or a state 
of terminal differentiation? It appears that, based on the 
immunological requirements, any B cell can acquire either 
effector or regulatory functions, or simultaneously exhibit 
both functions as seen with regulatory plasmablasts and 
Br1 cells (14, 53).
Recently published data suggest that B cells at different 
stages of development, from immature cells to terminally dif-
ferentiated plasma cells, can acquire suppressive functions 
indicating that Bregs are not a terminally differentiated state 
(13, 14). For these reasons, B-cell depletion therapies must 
be carefully designed as elimination of all B cells or certain 
B-cell subsets can result in an unexpected clinical response. 
Improved knowledge of Breg subsets, their role in differ-
ent stages of disease and how they are induced can pro-
vide new opportunities to develop novel therapies targeting 
Bregs. Therapies inducing Bregs in vivo or stimulating them 
in vitro by modulating the environmental milieu could provide 
several advantages over the currently used B-cell-depletion 
therapies.
Conclusion
The past decade has provided striking new insights into the 
diverse phenotypic and functional subsets of Bregs. The dif-
ferent diseases resulting from disruption of Breg homeosta-
sis emphasize the importance of immunosuppressive Bregs. 
Further investigation into Breg biology and the signals that 
drive Breg differentiation could provide ways of reshaping 
and resetting the immune system for better treatment of vari-
ous immune-related pathologies.
Acknowledgements
We would like to thank E. C. Rosser for her comments on the man-
uscript. M.M.  is funded by a Wellcome Trust project grant to C.M. 
(090406/Z/09/Z).
Conflict of interest statement: The authors declared no conflict of 
interests.
pre-Breg
Immature
Breg
MZ
Breg
Immature
Breg
Pb
Breg
Tim1
Breg
Plasma
Breg
B-10
Breg
Immature
B cell
Pb
Beff
Plasma
Beff
Plasma
Beff
Immature
Breg
MZ
Breg
Pb
Breg
Plasma
Breg
B CA
pre-Breg 
Immature
Breg
B-1a 
Breg
B-10 
Breg
pre-Breg pre-Breg 
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